Retinal microvascular network attenuation in Alzheimer's disease  by Williams, Michael A. et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 229-235Retinal microvascular network attenuation in Alzheimer’s diseaseMichael A. Williamsa,1, Amy J. McGowanb,1, Chris R. Cardwellb, Carol Y. Cheungc,d,
David Craige, Peter Passmoreb, Giuliana Silvestrif, Alexander P. Maxwellb, Gareth J. McKayb,*
aCentre for Medical Education, Queen’s University Belfast, Belfast, UK
bCentre for Public Health, Queen’s University Belfast, Belfast, UK
cSingapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
dOphthalmology and Visual Sciences Academic Clinical Programme, Duke-NUS Graduate Medical School, National University of Singapore,
Singapore, Singapore
eSouthern Health and Social Care Trust, Craigavon Hospital, Craigavon, UK
fCentre for Experimental Medicine, Queen’s University Belfast, Belfast, UKAbstract Introduction: Cerebral small-vessel disease has been implicated in the development of Alzheimer’sFinancial support:
Kingdom Grant MR/K
0004400. M.A. Willia
of Physicians/Dunhill
Alzheimer’s Research
betes UK PhD Studen
1Both authors hav
*Corresponding
2890235900.
E-mail address: g.
http://dx.doi.org/10.10
2352-8729/  2015 T
(http://creativecommodisease (AD). The retinal microvasculature enables the noninvasive visualization and evaluation of
the systemic microcirculation. We evaluated retinal microvascular parameters in a case-control study
of AD patients and cognitively normal controls.
Methods: Retinal images were computationally analyzed and quantitative retinal parameters
(caliber, fractal dimension, tortuosity, and bifurcation) measured. Regression models were used to
compute odds ratios (OR) and confidence intervals (CI) for AD with adjustment for confounders.
Results: Retinal images were available in 213 AD participants and 294 cognitively normal controls.
Persons with lower venular fractal dimension (OR per standard deviation [SD] increase, 0.77 [CI:
0.62–0.97]) and lower arteriolar tortuosity (OR per SD increase, 0.78 [CI: 0.63–0.97]) were more
likely to have AD after appropriate adjustment.
Discussion: Patients with AD have a sparser retinal microvascular network and retinal microvascular
variation may represent similar pathophysiological events within the cerebral microvasculature of pa-
tients with AD.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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ns.org/licenses/by/4.0/).The gold-standard for the diagnosis of AD is the identifica-
tion on post-mortem of amyloid-beta and neurofibrillary
tangles [2]. It is not clear how these pathologic features
result in the clinical manifestations of AD. Although AD
is described as a neurodegenerative condition, it is argued
that the failure of the “neurovascular unit” underlies the con-
dition [3]. Both structural and functional cerebral vascular
changes have been described in vivo and in animal models
of AD [4].
The cerebral and retinal vasculature share similar
embryologic origins, anatomic features, physiological prop-
erties, and regulatory mechanisms [5], and it is perhaps un-
surprising that retinal changes have also been observed in
AD [6–8]. Amyloid-beta has been identified in the retinaleimer’s Association. This is an open access article under the CC BY license
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[9]. Berisha and colleagues reported a significant difference
in the retinal venous blood column diameter between nine
patients with mild to moderate AD and eight controls
(P5 .01), with AD cases having narrower veins, and a reduc-
tion in blood flow (P 5 .002) [10]. Further support arose
from a much larger study, in which narrower retinal venules
and a sparser and more tortuous vessel network was
observed in 136 patients with AD compared with 290
matched cognitively normal controls [6].
There is now greater reliability in the assessment of a
wider range of retinal parameters beyond vessel caliber,
including fractal dimension, tortuosity, and vessel bifurca-
tion which provide a global indication of the “optimality”
and “efficiency” of blood distribution throughout the
retinal network [11–14]. These retinal features have
been postulated to reflect the integrity of the cerebral
microcirculation and have been associated with stroke,
implicating early microvascular network abnormalities in
the pathophysiology of these conditions [14–16].
Previous studies have shown association between retinal
vascular changes and AD, although the effects observed
have not always been either consistent or adjusted for
the potential confounding of medication use. Retinal
vascular changes identified in association with AD may
offer value both for understanding the disease etiology
and perhaps aid the early, noninvasive diagnosis of this
disease [17].
The aim of this study was to compare a spectrum of
retinal vascular parameters in a large sample consisting of
two cohorts, one of patients with AD and another of cogni-
tively normal controls. We hypothesize that changes within
the retinal microvascular network may reflect alterations
within the cerebral microcirculation of those with AD.2. Methods
2.1. Study population
This was a prevalent case-control study comparing
cases with AD to cognitively normal controls. All recruit-
ment and testing was performed by one investigator
(MW) and has been described elsewhere [18]. An oppor-
tunistic recruitment strategy was used. Potential cases
with AD were identified in a nonsystematic fashion as
they appeared in clinic or files from the population of
those with a diagnosis of AD, made by a senior clinician
using the National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer’s Dis-
ease and Related Disorders Association criteria [19],
attending a hospital memory clinic. Those with any other
type of dementia were not included, including vascular or
mixed dementia. Controls were recruited in several ways.
First, carers of patients attending any out-patient clinic in
the study hospital were approached as opportunities
arose. Second, a university press release generatedinterest. Third, controls asked friends to participate.
Finally, a series of talks given to AD patient support
groups in the region led to volunteers. Exclusion criteria
for controls were age under 65 years, Mini-Mental State
Examination (MMSE) score less than 26 of 30 and un-
masking of any ophthalmic history before recruitment.
Testing consisted of a questionnaire, blood pressure mea-
surement, and drawing of a blood sample to identify any
confounding factors. Ethical and clinical governance
approval was granted before the commencement of the
study. The study followed the tenets of the Declaration
of Helsinki.
2.2. Retinal photography and quantitative measurements
of retinal microvasculature
Retinal photography was performed through the dilated
pupil using a 500 Canon CR-DGi digital camera, after the
instillation of one drop of 1% tropicamide in all participants.
A semiautomated computer-assisted program (Singapore I
Vessel Assessment [SIVA], software version 3.0) was used
to quantitatively measure the retinal vascular parameters
from the photographs. SIVA automatically identifies the
optic disc, places a grid with reference to the center of the
optic disc, identifies vessel type, and calculates retinal
vascular parameters. A single trained grader (AMG),
blinded to participant characteristics, performed SIVA auto-
mated measurement and manual intervention if necessary,
according to a standardized protocol [20]. The measured
area was standardized and defined within the region between
0.5 and 2.0 disc diameters away from the disc margin, and all
visible vessels coursing through the specified zone were
measured (Fig. 1).
2.3. Retinal vascular caliber
Retinal vascular caliber was measured using the SIVA
program following the standardized protocol used in the
Atherosclerosis Risk in Communities study [21]. The retinal
arteriolar and venular calibers were summarized as central
retinal arterial equivalent (CRAE) and central retinal venular
equivalent (CRVE), respectively, according to the revised
Knudtson-Parr-Hubbard formula [22]. The reproducibility
of retinal vascular measurements was high, with intragrader
reliability assessed in 200 randomly selected retinal photo-
graphs and an intraclass correlation coefficient (95% confi-
dence interval [CI]) calculated as 0.98 (CI: 0.97–0.98) for
CRAE and 0.99 (CI: 0.99–0.99) for CRVE, respectively.
A high correlation between the right and left eyes in retinal
vascular measurements has been reported elsewhere [23].
Data from the right eye were used and when unavailable
was replaced by left eye data.
2.4. Retinal vascular fractal dimension
Total, arteriolar, and venular fractal dimensions were
determined from a skeletonized line tracing using the box
Fig. 1. Retinal fundus image assessed quantitatively using the Singapore I Vessel Assessment (SIVA) software. Arterioles are in red and venules in blue. The
measured area of retinal vascular parameters (caliber, fractal dimension, tortuosity, and branching angle) was standardized as the region from 0.5 to 2.0 optic
disc diameters from the disc margin.
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mary measure of the whole branching pattern of the retinal
vascular tree with larger values indicative of a more complex
branching pattern [24].2.5. Retinal vascular tortuosity
Retinal vascular tortuosity was estimated as the integral
of the curvature square along the path of the vessel
normalized by the total path length; this measure is dimen-
sionless because it represents a ratio measure [25]. These
estimates were summarized separately as retinal arteriolar
and venular tortuosity. Retinal vascular tortuosity reflects
the straightness/waviness of the vessels; a smaller tortuos-
ity value is indicative of a retinal vessel with a straighter
path.2.6. Retinal vascular branching angle
Retinal vascular branching angle was defined as the first
angle subtended between two daughter vessels at each
vascular bifurcation [26]. These estimates were summarized
as retinal arteriolar branching angle and retinal venular
branching angle, representing the average branching angle
of arterioles and venules, respectively.2.7. Other variables
The following potentially confounding variables were
measured, for inclusion in the conditional logistic regres-
sion modeling: age; gender; smoking (categorized aspresent, past, or never as per a previous study [27]); diag-
nosis of diabetes mellitus; diagnosis of cardiovascular
disease; diagnosis of cerebrovascular disease; diagnosis
of hypercholesterolemia; mean arterial blood pressure
(MABP); and medication use (aspirin/clopidogrel; beta-
blocker; calcium channel blocker; diuretic; nonsteroidal
anti-inflammatory drug; thyroxine).
2.8. Statistical analysis
All statistical analyses were performed using IBM
SPSS statistics version 21 (IBM Corp., Armonk, NY).
An independent t test or c2 test was used to compare
the characteristics of AD cases and controls in the study.
Quantitative retinal vascular parameters were analyzed as
continuous variables (and were standardized before entry
into regression models to give estimates per standard
deviation [SD] increase). Logistic regression models
were used to analyze the association of retinal vascular
parameters with AD. Multiple logistic regression models
were adjusted initially for gender, hypertension, smok-
ing, hypercholesterolemia, diabetes mellitus, history of
myocardial infarction to allow direct comparison to a
previous study [6] and were then additionally adjusted
for medications with a cohort frequency greater than
5% (aspirin/clopidogrel; beta-blocker; calcium channel
blocker; diuretic; nonsteroidal anti-inflammatory drug;
thyroxine). The models testing CRAE or CRVE related
to AD were additionally adjusted for fellow vessel caliber
to provide unbiased and biologically plausible results as
suggested previously [28].
Table 1
Summary statistics of participants
Characteristic
Cases,
n 5 213
Controls,
n 5 294 P
Mean age, yrs (SD) 79.6 (7.8) 76.3 (6.6) ,.001
Mean MMSE 19.0 (5.6) 28.9 (1.2) ,.001
Male, n (%) 77 (36) 116 (40) .45
Mean MABP (mmHg) 95.4 (10.6) 101.8 (10.6) ,.001
Ever smoked, n (%) 94 (46) 112 (38) .09
Current smoker, n (%) 14 (7) 15 (5) .42
Hypercholesterolemia, n (%) 80 (40) 116 (40) .88
Cardiovascular disease, n (%) 43 (21) 70 (24) .43
Cerebrovascular disease, n (%) 24 (12) 38 (12) .66
Hypertension, n (%) 78 (38) 124 (42) .34
Diabetes mellitus, n (%) 18 (9) 33 (11) .36
Aspirin/clopidogrel, n (%)* 98 (48) 108 (38) .02
Beta blockers, n (%)* 37 (18) 68 (25) .11
Calcium channel blockers, n (%)* 33 (16) 26 (10) .02
Diuretics, n (%)* 70 (35) 70 (25) .02
NSAIDs, n (%)* 10 (5) 20 (7) .34
Thyroxine, n (%)* 24 (12) 28 (10) .47
Abbreviations: SD, standard deviation; MMSE, Mini-Mental State
Examination; MABP, mean arterial blood pressure; NSAIDs, nonsteroidal
anti-inflammatory drugs.
*Medications taken with a frequency .5%.
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Table 1 shows the summary characteristics of the AD
(n5 213) and cognitively normal control (n5 294) groups.
There were no significant differences in gender, smoking
status, hypercholesterolemia, cardiovascular disease, cere-
brovascular disease, or diabetes mellitus between groups.
AD patients were more likely to be older than controls
(79.6 vs. 76.3 yrs), and have a lower MMSE score (19.0
vs. 28.9) and MABP (95.4 vs. 101.8 mmHg) than control
subjects. A significantly greater number of AD patientsTable 2
Comparisons of retinal vascular parameters between AD cases and controls
Parameter
AD cases,
n 5 213
Controls,
n 5 294
PMean (SD) Mean (SD)
Caliber
Central retinal arteriolar
equivalent, mm
112.8 (10.3) 110.8 (10.5) .029
Central retinal venular
equivalent, mm
159.0 (16.3) 158.9 (15.3) .951
Fractals
Total fractal dimension 1.396 (0.053) 1.412 (0.053) .001
Arteriolar fractal dimension 1.194 (0.059) 1.206 (0.062) .024
Venular fractal dimension 1.165 (0.050) 1.184 (0.050) ,.001
Tortuosity
Arteriolar tortuosity (!104) 0.876 (0.228) 0.921 (0.228) .030
Venular tortuosity (!104) 1.016 (0.276) 1.035 (0.294) .458
Bifurcations
Arteriolar branching angle,  78.30 (14.82) 79.17 (15.31) .523
Venular branching angle,  80.38 (12.60) 79.86 (9.90) .599
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation.
NOTE. P values were calculated by independent sample t test.were more likely to be taking the following medications:
aspirin/clopidogrel (48% vs. 38%), calcium channel
blockers (16% vs. 10%), and diuretics (35% vs. 25%).
Gradable retinal images of sufficient quality for vessel
assessment were available for all 507 participants. Table 2
shows the comparisons of retinal parameters between the
AD and control groups. AD patients had significantly lower
fractal dimensions (PTotal 5 .001; PArteriolar 5 .024;
PVenular , .001), wider (P 5 .029) but less tortuous retinal
arterioles (P 5 .03). No significant variations in venular
caliber, arteriolar, or venular branching angles or venular
tortuosity were detected in the unadjusted analysis between
both groups (P . .05).
Table 3 shows the associations between AD and retinal
vascular parameters. In the multivariate logistic regres-
sion, persons with lower venular fractal dimension (OR
per SD increase, 0.77 [CI: 0.62–0.97]) and lower arteri-
olar tortuosity (OR per SD increase, 0.78 [CI: 0.63–
0.97]) were more likely to have AD after the adjustment
for age, gender, smoking status, hypercholesterolemia,
diabetes mellitus, a history of cardiovascular disease, a
history of cerebrovascular disease, MABP, and medica-
tions with a frequency .5% use (aspirin/clopidogrel;
beta-blocker; calcium channel blocker; diuretic; nonste-
roidal anti-inflammatory drug; thyroxine). A secondary
analysis conducted in all participants and separately in
AD cases only failed to detect any significant associa-
tions between retinal microvascular parameters and
MMSE score.4. Discussion
This was the largest case-control study of which we are
aware to compare retinal vascular parameters in subjects
with AD and cognitively normal controls. Our study has
shown that patients with AD are more likely to undergo
structural changes in the retinal microvasculature mani-
festing in a sparser microvascular network which may
reflect similar changes ongoing within the cerebral micro-
circulation. As expected the MMSE scores were signifi-
cantly lower (P , .001) in the AD cohort compared with
the controls and the range of scores in the AD cohort, of
1 to 29, reflected the large range of AD severity included
within the study.
Overlapping risk factors for both AD and vascular dis-
ease support a role for systemic microvascular dysfunc-
tion in the pathologic changes that occur during AD
pathogenesis. Retinal vessel tortuosity is reported to be
the first vascular change identified in “many retinopa-
thies” and may reflect changes in blood viscosity [29].
One study found whole blood viscosity to be significantly
greater in AD cases than in age-matched controls
(P , .05), and viscosity was related in the same study
to a composite conjunctival microvascular index, based
on vessel diameter, blood flow, and “microvascular
abnormalities” [30]. Tortuosity is a common feature in
Table 3
Associations between AD and retinal vascular parameters
Parameter
Model 1 Model 2 Model 3
OR (95% CI); P OR (95% CI); P OR (95% CI); P
Caliber
Central retinal arteriolar equivalent per SD increase* 1.37 (1.08–1.75); .010 1.17 (0.89–1.53); .267 1.11 (0.83–1.47); .481
Central retinal venular equivalent per SD increasey 0.87 (0.69–1.11); .269 0.98 (0.74–1.29); .867 0.99 (0.75–1.32); .960
Fractals
Total fractal dimension per SD increase 0.84 (0.70–1.02); .073 0.86 (0.70–1.06); .154 0.85 (0.68–1.06); .141
Arteriolar fractal dimension per SD increase 0.92 (0.76–1.11); .373 0.92 (0.75–1.13); .413 0.92 (0.74–1.14); .436
Venular fractal dimension per SD increase 0.75 (0.62–0.91); .004 0.78 (0.63–0.97); .024 0.77 (0.62–0.97); .025
Tortuosity
Arteriolar tortuosity per SD increase 0.82 (0.68–0.99); .042 0.80 (0.65–0.99); .041 0.78 (0.63–0.97); .027
Venular tortuosity per SD increase 0.96 (0.80–1.16); .964 1.01 (0.83–1.24); .911 1.01 (0.82–1.24); .952
Bifurcation
Arteriolar branching angle per SD increase 0.95 (0.79–1.14); .581 0.96 (0.78–1.18); .684 0.91 (0.73–1.14); .414
Venular branching angle per SD increase 1.08 (0.90–1.29); .404 1.03 (0.84–1.26); .791 1.10 (0.89–1.36); .389
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; OR, odds ratio; CI, confidence intervals.
NOTE. Model 1 was adjusted for age and gender. Model 2 was adjusted for age, gender, mean arterial blood pressure, smoking status, hypercholesterolemia,
diabetesmellitus, and history of cardiovascular disease.Model 3 was adjusted for model 2 covariates, cerebrovascular disease, andmedications with a frequency
.5% (aspirin/clopidogrel, beta blockers, calcium channel blockers, diuretics, nonsteroidal anti-inflammatory drugs, thyroxine).
*Additionally adjusted for central retinal venular equivalent.
yAdditionally adjusted for central retinal arteriolar equivalent.
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ease and aging, yet the underlying mechanisms for its
initiation and development remain unclear. Multiple fac-
tors have been implicated in the process of vascular tor-
tuosity including genetic factors, degenerative vascular
disease, and alteration in blood flow and pressure, which
may result in vessel buckling through the alteration of the
properties of the vascular wall [31]. Mechanical insta-
bility and remodeling may offer mechanistic insight
into the initiation and development of increasing blood
vessel tortuosity [31].
Published data supporting a role for etiological abnormal-
ities of the cerebral microcirculation in AD is sparse due to
the difficulties associated with visualizing it. Our data sug-
gest it is plausible changes in the retinal microvasculature
in AD may represent similar pathologic changes ongoing
in the cerebral microvascular network. Previously published
data have identified narrower venular caliber in association
with AD [6], although this effect has not always been consis-
tently observed [32]. More recently, fractal analysis has been
used to evaluate microvascular health with smaller fractal
dimension values representing a sparser retinal network,
more commonly associated with ill health. Several indepen-
dent investigations have consistently identified a sparser
retinal fractal network in association with AD [6] and
cognitive impairment [33,34] and indeed with other
conditions which have an underlying microvascular
component [14–17].
The major strengths of our study were the large num-
ber of subjects, the range of severity of AD cases
included, the number of potentially confounding factors
measured, and the automated nature of measurements
captured, which reduces the potential for measurementbias. Our study focused solely on AD to the exclusion
of other dementia subtypes, such as vascular dementia.
In addition, we have evaluated retinal fundus images us-
ing a validated computer-assisted program and standard-
ized assessment of a range of vascular risk factors. There
are several potential weaknesses to our study. First, there
may be residual confounding factors not measured in our
cohort that influence retinal microvascular variation but
which have not been controlled for in our data. For
example, changes in retinal vessel caliber can vary by
up to 17% for arterioles and up to 11% for venules during
one cardiac cycle [35]. Assuming that retinal images
were captured randomly during the cardiac cycle, our
findings related to vascular caliber, could potentially be
confounded. Retinal arterial narrowing has also been
reported in association with cerebral small vessel disease
[36]. The degree of cerebral vascular changes in our
sample of AD cases was unknown, although all had
computerized tomography scans for diagnostic purposes
and cardiovascular risk factors were adjusted for. Second,
uncertainty in the pathology underlying clinical diagno-
ses of AD is a potential problem common to all ante-
mortem studies on AD, despite the use of standardized
clinical diagnostic criteria [37]. Third, the causal
and temporal relationships between the retinal microvas-
culature and AD cannot be determined due to the
cross-sectional nature of our study. Finally, recall bias
may have led to underestimates of the prevalence of
confounding factors in cases, despite a carer always
being present and medical notes being consulted when
needed.
Our investigation may offer further insight into the
vascular contribution to the pathophysiology of AD.
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are seen in early AD, but as both are common with
increasing age, they would be expected to coexist. The
relationship between cerebral vascular changes and
the degenerative changes characteristic of AD is unclear:
amyloid plaques may contribute to vascular damage, or
vice versa [38]. In the Rotterdam study [39], cerebral
hypoperfusion was associated with a greater risk of
dementia although reduced cerebral blood flow may sim-
ply reflect reduced demands of an atrophying brain.
Previous investigations in a mouse model of AD have
suggested amyloid accumulation in vessel walls increases
their rigidity and thus impairs autoregulation; the conse-
quent reduced vascular pulsation leads to less clearance
of soluble amyloid-beta [40]. Vascular dysfunction may
switch on hypoxia-induced pathways, which may
contribute to the development of AD through increasing
amyloid-beta load [41] or tau pathology [42]. It is perti-
nent to note that many risk factors for AD are also
vascular risk factors, such as hypertension, diabetes mel-
litus, and dyslipidemia. The clinical relevance of the
potentially underlying role of vascular dysfunction in
AD is not established. A systematic review on transcra-
nial Doppler suggested that the method offered a nonin-
vasive, inexpensive, and portable means to measure
cerebral blood flow, and could discriminate between de-
mentia and normal ageing, perhaps also distinguishing
AD from vascular dementia [43].
Hypertension is a modifiable risk factor for dementia.
Published evidence identifies impaired cerebral blood
flow and whole brain atrophy as common early symptoms
contributing to memory loss [44]. Despite this well-
documented association, few current treatment options
for dementia are directed at this potential therapeutic
target [45]. Cross-sectional studies have consistently sup-
ported moderately strong associations between dementia
and brain imaging abnormalities that highlight the impor-
tance of vascular disease as the underlying pathophysi-
ology of cognitive decline [46]. Early detection is
critical for the timely diagnosis of dementia and clinical
intervention. However, as the earliest indicators of brain
microvascular pathology are seldom detectable by mag-
netic resonance imaging, research to improve our
understanding of AD pathogenesis, and earlier disease
predictors, can improve patient care [47,48]. Clearly the
retina is easier to examine both clinically and by
noninvasive imaging modalities than the brain, and
retinal vascular parameters, including those measured in
this study, may serve as surrogate markers in evaluating
the effectiveness of novel treatments for AD.
In conclusion, the identification of retinal changes in
patients with AD may aid our understanding of this condi-
tion. Future studies with preclinical AD patients may offer
potential promise for the earlier identification of AD for
those at increased disease risk before significant cognitive
difficulties emerge.RESEARCH IN CONTEXT
1. Systematic review: We searched PubMed until
January 31, 2015, for articles published in English
with the search terms “retinal microvascular abnor-
malities”, “dementia”, and “Alzheimer’s disease”.
We also reviewed reference lists of publications iden-
tified from this search, in addition to other relevant
papers on retinal parameters.
2. Interpretation: Vascular mechanisms have been pro-
posed as contributory factors in the development of
Alzheimer’s disease (AD). Noninvasive visualization
of the human microcirculation through the retinal
vasculature may reflect ongoing cerebral microvas-
cular pathology. In this study, we have identified a
sparser retinal microvascular network in patients
with AD represented by a reduced venular fractal
dimension and arteriolar tortuosity compared with
cognitively normal controls, possibly reflecting
similar alterations in cerebral microcirculation.
3. Future directions: Retinal microvascular imaging
may enable better differentiation of pathophysiolog-
ical dementia subtypes, improved stratification of
those at increased risk of AD, and further insights
into the mechanisms that contribute to the ongoing
processes of AD pathology. Retinal microvascular
measures may offer inexpensive surrogate measure-
ment for evaluating future novel AD treatments for
the improvement of cerebral blood flow.References
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